Avalo Therapeutics shares are trading lower on continued downward momentum after the company yesterday announced its Phase 2 Peak trial For quisovalimab In patients With non-eosinophilic asthma missed its primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
Avalo Therapeutics' stock is trading lower due to continued downward momentum after the company announced that its Phase 2 Peak trial for quisovalimab in patients with non-eosinophilic asthma missed its primary endpoint.
June 27, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Avalo Therapeutics' shares are trading lower after the company's Phase 2 Peak trial for quisovalimab in non-eosinophilic asthma patients missed its primary endpoint.
Avalo Therapeutics' stock is trading lower due to the negative news of its Phase 2 Peak trial for quisovalimab missing its primary endpoint. This indicates that the drug may not be as effective as initially hoped, which could impact the company's future revenue and growth prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100